Literature DB >> 14767488

Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray.

Hongbin Zha1, Mark Raffeld, Lu Charboneau, Stefania Pittaluga, Larry W Kwak, Emanuel Petricoin, Lance A Liotta, Elaine S Jaffe.   

Abstract

Overexpression of Bcl-2 protein has been known to play a role in the pathogenesis of follicular lymphoma (FL). However, 10-15% of FLs are negative for Bcl-2 by immunohistochemistry, raising the possibility that another gene product(s) may provide prosurvival signal(s). We used reverse phase protein microarray to analyze lysates of follicle center cells isolated by laser capture microdissection from: Bcl-2+ FL, Bcl-2- FL and reactive follicular hyperplasia (FH) (nine cases each group). TUNEL assay confirmed similar and reduced levels of apoptosis in Bcl-2+ FL and Bcl-2- FL, indicating the likelihood of Bcl-2-independent inhibition of apoptosis. Arrays were quantitatively analyzed with antibodies to proteins involved in the apoptotic pathway. As expected, Bcl-2 levels were up to eight-fold higher in Bcl-2+ FL than in FH and Bcl-2- FL. However, there was no difference in levels of Mcl-1 and survivin among these three groups. Bcl-X(L) showed a trend for increased expression in Bcl-2- FL as compared with Bcl-2+ FL, although the differences did not reach statistical significance (P>0.1). The increase in Bcl-X(L) may provide an alternative antiapoptotic signal in FL negative for Bcl-2 protein. Interestingly, Bax expression was higher in FL (Bcl-2+ or -) than in FH (P=0.001). Notably, phospho-Akt (Ser-473) was increased in FL (Bcl-2+ or -) (P<0.03) with increased phospho-Bad (Ser-136), as compared with levels in FH. The activation of the Akt/Bad pathway provides further evidence of prosurvival signals in FL, independent of Bcl-2 alone. These data suggest that nodal FL represents a single disease with a final common biochemical pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767488     DOI: 10.1038/labinvest.3700051

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  18 in total

1.  Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections.

Authors:  José Vassallo; Talal Al Saati; Randy D Gascoyne; Kathyrn Welsh; John C Reed; Pierre Brousset; Georges Delsol
Journal:  J Hematop       Date:  2010-01-30       Impact factor: 0.196

2.  The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.

Authors:  S Kheirallah; S Fruchon; L Ysebaert; A Blanc; F Capilla; A Marrot; T Alsaati; F X Frenois; K A Benhadji; J J Fournié; G Laurent; C Bezombes
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 3.  Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.

Authors:  Manfred Dietel; Christine Sers
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

4.  Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.

Authors:  Jonathan H Schatz
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

Review 5.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

6.  Variable slope normalization of reverse phase protein arrays.

Authors:  E Shannon Neeley; Steven M Kornblau; Kevin R Coombes; Keith A Baggerly
Journal:  Bioinformatics       Date:  2009-03-31       Impact factor: 6.937

Review 7.  The PI3K pathway in B cell metabolism.

Authors:  Julia Jellusova; Robert C Rickert
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-08-05       Impact factor: 8.250

8.  Indolent lymphoma: diagnosis and prognosis in medical practice.

Authors:  Anca Ciobanu; Oana Stanca; Irina Triantafyllidis; Anca Lupu
Journal:  Maedica (Buchar)       Date:  2013-09

9.  Application of physicochemically modified silicon substrates as reverse-phase protein microarrays.

Authors:  A Jasper Nijdam; Michael R Zianni; Edward E Herderick; Mark M-C Cheng; Jenifer R Prosperi; Fredika A Robertson; Emanuel F Petricoin; Lance A Liotta; Mauro Ferrari
Journal:  J Proteome Res       Date:  2009-03       Impact factor: 4.466

10.  IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.

Authors:  Katherine R Calvo; Bhavana Dabir; Alexandra Kovach; Christopher Devor; Russell Bandle; Amelia Bond; Joanna H Shih; Elaine S Jaffe
Journal:  Blood       Date:  2008-08-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.